Cocrystal Pharma - שווי חברה להכנסות COCP

Cocrystal Pharma, Inc. (COCP) utilizes a CDMO network for drug production, and its financial stability depends on external funding due to a lack of profitable products. The current price-to-sales valuation reflects the fundamental value trend, where 34883.72 is the current level of the metric. Meanwhile, robotic synthesis and computer modeling accelerate the search for active molecules without increasing headcount.
פילוחי מדדים פיננסיים ומדדי שוק עבור Cocrystal Pharma (COCP)

Cocrystal Pharma, Inc. (COCP) focus on developing antiviral small molecules within clinical trials makes revenue an unstable factor, necessitating a business valuation based on enterprise value minus net debt. This metric determines the real price of the asset relative to sales volume; therefore, the current enterprise value-to-revenue ratio allows for the identification of either a risk of overpayment or an undervaluation of capital.